| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1345/APH.1G079 |
| P698 | PubMed publication ID | 16204394 |
| P2093 | author name string | Mark T Holdsworth | |
| Thuy Vo-Nguyen | |||
| P2860 | cites work | The continuing unethical use of placebo controls | Q28244803 |
| Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy | Q28364205 | ||
| Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance | Q32063216 | ||
| Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology | Q33880234 | ||
| Equipoise and the ethics of clinical research | Q34050273 | ||
| The ethical analysis of risk | Q34228763 | ||
| Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy | Q35568094 | ||
| Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists | Q36431212 | ||
| Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin | Q36832481 | ||
| Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials | Q36905066 | ||
| Combination of transcutaneous electrical nerve stimulation and ondansetron in preventing cisplatin-induced emesis | Q39416550 | ||
| Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma | Q40597777 | ||
| Views of American oncologists about the purposes of clinical trials | Q40614974 | ||
| Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study | Q42624694 | ||
| Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration | Q43516796 | ||
| Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone | Q43543624 | ||
| Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy | Q43562737 | ||
| Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis | Q43582725 | ||
| Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy | Q43735498 | ||
| Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis | Q43807560 | ||
| Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation | Q43835952 | ||
| Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study | Q43837397 | ||
| Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. | Q44062377 | ||
| Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting | Q44092953 | ||
| Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron | Q44092956 | ||
| Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer | Q44232936 | ||
| A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis | Q44299829 | ||
| Reduced maintenance of complete protection from emesis for women during chemotherapy cycles | Q44308882 | ||
| Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. | Q44415307 | ||
| Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America | Q44464294 | ||
| Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. | Q44490963 | ||
| Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan | Q44502218 | ||
| Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours | Q44529396 | ||
| Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron | Q44592616 | ||
| High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability | Q44613268 | ||
| The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St | Q44618271 | ||
| Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy | Q44618275 | ||
| Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron | Q44667127 | ||
| A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? | Q44690541 | ||
| The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical | Q44744702 | ||
| Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study | Q44754098 | ||
| Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. | Q44765706 | ||
| Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients--a randomized study | Q44809437 | ||
| Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study | Q44864323 | ||
| Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research. | Q51025001 | ||
| The integral role of clinical research in clinical care. | Q53392261 | ||
| The therapeutic orientation to clinical trials. | Q53392264 | ||
| Psychiatry. Are placebo-controlled drug trials ethical? | Q53522579 | ||
| Management of cyclophosphamide-induced emesis over repeat courses. | Q53622835 | ||
| Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. | Q53901789 | ||
| On the receiving end--patient perception of the side-effects of cancer chemotherapy. | Q55062718 | ||
| Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation | Q56890355 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1903-1910 | |
| P577 | publication date | 2005-10-04 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting | |
| P478 | volume | 39 |
Search more.